[{"orgOrder":0,"company":"St. Jude Children","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Streptococcus Pneumoniae Vaccine","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Blue Water Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"St. Jude Children \/ Blue Water Vaccines"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"St. Jude Children \/ n-Lorem Foundation"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"St. Jude Children \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children \/ Renaissance Pharma"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ AbbVie Inc"}]

Find Clinical Drug Pipeline Developments & Deals by St. Jude Children

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : The collaboration aims to accelerate the development of optimized experimental antisense oligonucleotide (ASO) medicines for pediatric patients with extremely rare genetic neurological disorders.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          April 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Discovery

                          Sponsor : n-Lorem Foundation

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.

                          Product Name : Hu14.18K322A

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 08, 2023

                          Lead Product(s) : Dinutuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Renaissance Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Blue Water Vaccines has entered into an exclusive worldwide license agreement for the development of a Streptococcus Pneumoniae vaccine with St. Jude Children's Research Hospital.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          October 02, 2020

                          Lead Product(s) : Streptococcus Pneumoniae Vaccine

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Undisclosed

                          Sponsor : Blue Water Vaccines

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : In the Phase 1 study, Venetoclax with Navitoclax and chemotherapy was well tolerated and had promising efficacy in heavily pretreated pediatric patients with ALL and LL.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 12, 2020

                          Lead Product(s) : Venetoclax,Navitoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : AbbVie Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank